Leishmaniasis is a widespread parasitic disease prevalent in less developed countries for which few effective treatments are available. Studies have shown that compounds active against Hsp90 are also active against <i>Leishmania donovani</i> cells. Our lab is currently investigating Hsp90 inhibitors with the goal of discovering new antileishmaniasis agents. Our project consists of making analogs to the tetrahydroindazole core of the Hsp90 inhibitor SNX 2112 in order to explore increased binding within the active site in an attempt to increase antileishmanial activity.

Studies aimed at the synthesis of Hsp90 inhibitors as antileishmaniasis agents

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.